Simon Kiddle > Mewburn Ellis LLP > Bristol, England > Lawyer Profile
Mewburn Ellis LLP Offices
AURORA BUILDING
COUNTERSLIP
BRISTOL
BS1 6BX
England
- Firm Profile
- Go to...
Simon Kiddle
Work Department
Head of Life Sciences
Position
Partner, Patent Attorney
Career
Simon has nearly 30 years’ experience in original patent drafting, patent strategy European oppositions and appeals, including complex multi-party proceedings, and due diligence work, across the life sciences field for both large and small molecule therapeutics. He has worked on the portfolios covering many top selling biologics and has been at the forefront of patenting in the field of precision medicine and life cycle management for therapeutics. Simon heads up the firm’s Life Sciences practice group and is a member of our Management Board.
Simon works with large and small biotech companies, universities and research charities. He also advises start-up companies and investors in patent strategy.
Education
Simon has a chemistry degree from Oxford University. He joined Mewburn Ellis in 1991, qualifying as a Chartered Patent Attorney in 1994 and a European Patent Attorney the following year. He joined the partnership in 1997.
Lawyer Rankings
London > TMT (technology, media and telecoms) > PATMA: Patent attorneys
Mewburn Ellis LLP’s ‘excellent team’ benefits from the firm’s strong geographical footprint; with offices in London, Bristol, Manchester, Cambridge, and Munich, the practice is able to seamlessly advise clients on UK and German patent filing and prosecution matters, in addition to opposition proceedings before the EPO. Manchester-based Graeme Moore leads the growing engineering and ICT group, while Bristol-based Simon Kiddle heads up the life sciences team, which is notable for its expertise in emerging technical areas, such as bioinformatics, advanced therapeutics, antibodies, and precision medicine. Jeremy Webster leads the chemistry group from Manchester, which handles a wide range of chemical innovation patents, from dyes, drugs, and catalysts, to composites, polymers, and pesticides. Biopharma specialist Robert Andrews remains as the firm’s first chief inclusion and diversity officer.